The North America Legionella Testing Market would witness market growth of 8.9% CAGR during the forecast period (2023-2030).
Legionellosis is a severe respiratory disorder caused by Legionella. The health disorder is a serious concern and requires hospitalization and intensive care. The escalating incidence of Legionellosis has correspondingly heightened the need for disease management strategies. Effective disease management necessitates the implementation of appropriate diagnostic and therapeutic approaches. Thus, increasing demand for rapidly advanced diagnostic techniques is likely to drive the growth of the market.
The testing involves examining and evaluating Legionella bacteria in diverse environments, including cooling towers, water systems, and other areas where the growth of Legionella bacteria could potentially endanger human health. Water treatment companies, testing laboratories, healthcare facilities, and government organizations tasked with overseeing and regulating Legionella control measures are all participants in the market. The testing is an essential component in the prevention and management of Legionnaires' disease as it permits the identification and remediation of Legionella bacteria across diverse environments, thereby ensuring the protection of public health.
In the 2021 Census, the number of Canadians aged eighty-five and older surpassed 861,000, a rise of more than twofold compared to the 2001 Census, according to Statistics Canada. Over the age of 85, the population has increased by 12% since 2016, making it one of the age groups experiencing the most rapid development. At present, 2.3% of the population is aged 85. In the twenty-five years leading up to 2046, the elderly population could nearly triple to 2.5 million individuals. Thus, the growing elderly population of the region is impacting the market positively.
The US market dominated the North America Legionella Testing Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $149,723.8 Thousand by 2030. The Canada market is experiencing a CAGR of 11.3% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 10.4% during (2023 - 2030).
Based on Type, the market is segmented into Polymerase Chain Reaction (PCR), Culture Media, Urine Antigen Testing (UAT), Serology, and Direct Fluorescent Antibody (DFA) Test. Based on End-User, the market is segmented into Clinical Laboratories, Hospitals & Clinics, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Legionella Testing Market is Predict to reach $578.9 Million by 2030, at a CAGR of 9.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include QuidelOrtho Corporation, Abbott Laboratories, Merck KGaA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton Dickinson and Company, BioMerieux S.A., IDEXX Laboratories, Inc., Eurofins Scientific SE and Qiagen N.V
By Type
By End-User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
